OX40L [R4930 (Oxelumab)] Antibody from MYBIOSOURCE INC.

Search, find, compare suppliers for anti-OX40L [R4930 (Oxelumab)] antibody, protein, ELISA kits.

Edit 
Antigenic SpecificityOX40L [R4930 (Oxelumab)]
Clonepolyclonal
Host SpeciesRabbit
Reactive Specieshuman
Isotypen/a
FormatProtein A purified
Size0.2 mg
Concentrationn/a
ApplicationsBlock, Flow Cytometry (FC/FACS)
Reviews / RatingsIf you have used this antibody, please help fellow researchers by submitting reviews to pAbmAbs and antYbuddY.
DescriptionSpecificity: Binds to human OX40L. Recombinant monoclonal antibody to OX40L. Manufactured using a Recombinant Platform with variable regions (i.e. specificity) from the therapeutic antibody R4930 (Oxelumab). This chimeric rabbit antibody was made using the variable domain sequences of the original Human IgG1 format, for improved compatibility with existing reagents, assays and techniques.
ImmunogenImmunogen: Oxelumab binds to human OX40L, the ligand of OX40, stimulatory receptor that is expressed on activated T cells, natural killer (NK) cells and natural killer T (NKT) cells. Chimeric Use Statement: This chimeric rabbit antibody was made using the variable domain sequences of the original Human IgG1 format, for improved compatibility with existing reagents, assays and techniques.
Other Names[TNFSF4; tumor necrosis factor (TNF) superfamily member 4; OX40 ligand; OX-40L; TAX transcriptionally-activated glycoprotein 1; TXGP1; gp34; CD252], [TNFSF4; TNFSF4; GP34; CD252; OX4OL; TXGP1; CD134L; OX-40L; TNLG2B; TXGP1; OX40L]
Gene, Accession #[OX40L], Gene ID: 7292
Catalog #MBS488213
Price$425
Order / More InfoOX40L [R4930 (Oxelumab)] Antibody from MYBIOSOURCE INC.
Product Specific Referencesn/a
MYBIOSOURCE INC.
MYBIOSOURCE INC.
MYBIOSOURCE INC.
P.O. Box 153308
San Diego CA 92195-3308
P: 1.858.633.0165
P: 1.888.MBS.0165 (1.888.627.0165) (US & Canada)
F: 1.858.633.0166

sales@mybiosource.com

http://www.MyBioSource.com

Profile of MYBIOSOURCE INC.
Return to Antibodies

© 1980 - 2024 Linscott's Directory, Linscott's USA. All rights reserved.